Treatment of opportunistic mycoses: how long is long enough?

被引：29

作者：

Singh, N ^{[1
]}

机构：

[1] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA

来源：

LANCET INFECTIOUS DISEASES | 2003年 / 3卷 / 11期

关键词：

D O I：

10.1016/S1473-3099(03)00802-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

For most opportunistic mycoses no optimum duration of antifungal therapy has been defined. Although a long course of therapy is prudent, especially for mycelial fungal infections, excessively and unnecessarily extended courses of treatment incur a risk of toxicity and the expense of the therapeutic regimen. On the basis of existing reports on the pathogenesis and the effect of duration of therapy and other variables on outcome and response rate in fungal infections, this review proposes guidelines that may facilitate a rational approach to decision-making about the duration of antifungal therapy.

引用

页码：703 / 708

页数：6

共 40 条

[31] Practice guidelines for the treatment of candidiasis [J].

Rex, JH ;

Walsh, TJ ;

Sobel, JD ;

Filler, SG ;

Pappas, PG ;

Dismukes, WE ;

Edwards, JE .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :662-678

[32] A RANDOMIZED TRIAL COMPARING FLUCONAZOLE WITH AMPHOTERICIN-B FOR THE TREATMENT OF CANDIDEMIA IN PATIENTS WITHOUT NEUTROPENIA [J].

REX, JH ;

BENNETT, JE ;

SUGAR, AM ;

PAPPAS, PG ;

VANDERHORST, CM ;

EDWARDS, JE ;

WASHBURN, RG ;

SCHELD, WM ;

KARCHMER, AW ;

DINE, AP ;

LEVENSTEIN, MJ ;

WEBB, CD .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (20) :1325-1330

[33] Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation [J].

Ribaud, P ;

Chastang, C ;

Latgé, JP ;

Baffroy-Lafitte, L ;

Parquet, N ;

Devergie, A ;

Espérou, H ;

Sélimi, F ;

Rocha, V ;

Derouin, F ;

Socié, G ;

Gluckman, E .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) :322-330

[34] EFFICACY OF AMPHOTERICIN-B ENCAPSULATED IN LIPOSOMES (AMBISOME) IN THE TREATMENT OF INVASIVE FUNGAL-INFECTIONS IN IMMUNOCOMPROMISED PATIENTS [J].

RINGDEN, O ;

MEUNIER, F ;

TOLLEMAR, J ;

RICCI, P ;

TURA, S ;

KUSE, E ;

VIVIANI, MA ;

GORIN, NC ;

KLASTERSKY, J ;

FENAUX, P ;

PRENTICE, HG ;

KSIONSKI, G .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 :73-82

[35] VENOUS CATHETER-ASSOCIATED CANDIDEMIA [J].

ROSE, HD .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1978, 275 (03) :265-269

[36] Practice guidelines for the management of cryptococcal disease [J].

Saag, MS ;

Graybill, RJ ;

Larsen, RA ;

Pappas, PG ;

Perfect, JR ;

Powderly, WG ;

Sobel, JD ;

Dismukes, WE .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :710-718

[37] Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices [J].

Singh, N .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1692-1696

[38] Cytomegalovirus infection of liver transplant recipients: Comparison of antigenemia and molecular biology assays [J].

Singh, N .

LIVER TRANSPLANTATION, 2001, 7 (11) :1004-1007

[39]

SINGH N, 2002, 42 INT C ANT AG CHEM

[40] Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome [J].

vanderHorst, CM ;

Saag, MS ;

Cloud, GA ;

Hamill, RJ ;

Graybill, JR ;

Sobel, JD ;

Johnson, PC ;

Tuazon, CU ;

Kerkering, T ;

Moskovitz, BL ;

Powderly, WG ;

Dismukes, WE ;

Riser, L ;

Thomas, C ;

Lacke, C ;

White, AC ;

Patterson, S ;

Davis, D ;

Flanigan, C ;

Harden, T ;

Phillips, D ;

Ullom, I ;

Vasquez, J ;

McMullen, S ;

Flowers, D ;

Bosha, M ;

Britton, M ;

Fisher, JF ;

Newman, C ;

Willis, B ;

Henderson, H ;

Johnson, E ;

Dungo, L ;

Pierce, M ;

Morgan, M ;

Stern, J ;

Petrosky, N ;

Bamberger, D ;

Farnan, R ;

Feinberg, J ;

Apuzzo, L ;

Royal, W ;

Thompson, S ;

Barrett, K ;

Kauffman, C ;

Gutsch, H ;

McKinsey, D ;

Lee, B ;

Hyslop, N ;

Greenspan, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (01) :15-21

← 1 2 3 4 →